Back
Halozyme Therapeutics Stock Predictions
Sponsored
HALO
Sponsored
Invest. Do Good. Get Rewarded. Just $0.25/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
44
HALO
Halozyme Therapeutics
Last Price:
45.73
Seasonality Move:
17.34%
7 Day Trial
ALL ACCESS PASS
$
7
Start Investing Smarter Unlock Louis Navellier's Stock Grader for free
Louis' clients have paid up to $30,000 for these insights - now you can try it at no cost.Halozyme Therapeutics Stock Forecast
- Over the next 52 weeks, Halozyme Therapeutics has on average historically risen by 29.7% based on the past 20 years of stock performance.
- Halozyme Therapeutics has risen higher in 12 of those 20 years over the subsequent 52-week period, corresponding to a historical accuracy of 60%
-
Is Halozyme Therapeutics Stock Undervalued?
The current Halozyme Therapeutics [HALO] share price is $45.76. The Score for HALO is 44, which is 12% below its historic median score of 50, and infers higher risk than normal. - HALO is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
Will Halozyme Therapeutics Stock Go Up Next Year?
- Over the next 52 weeks, Halozyme Therapeutics has on average historically risen by 29.7% based on the past 20 years of stock performance.
Halozyme Therapeutics Stock Rating
Sell
44
Halozyme Therapeutics (HALO)
is a Sell
Is Halozyme Therapeutics overpriced?
- Halozyme Therapeutics has risen higher in 12 of those 20 years over the subsequent 52-week period, corresponding to a historical accuracy of 60%
Halozyme Therapeutics Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
halozyme.com
52-Week Data
52-Week High:
65.53
52-Week Low:
33.15
Prediction Charts
Market Cap:
5.82B
Price in USD:
45.76
Volume:
1.85M
Beta:
1.48
Technical Analysis
SMA50:
55.29
SMA100:
56.04
SMA200:
49.09
52-Wk Change:
14.37%
Stock Predictions
-
Is Halozyme Therapeutics stock public?
Yes, Halozyme Therapeutics is a publicly traded company. -
What is the Halozyme Therapeutics stock quote today?
The Halozyme Therapeutics stock price is 45.76 USD today. -
How to buy Halozyme Therapeutics stock online?
You can buy Halozyme Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
Date | Opening | Closing | Minimum | Maximum |
---|---|---|---|---|
Nov-1 | 55.66 | 57.15 | 57.62 | 52.56 |
Nov-4 | 56.82 | 58.46 | 59.39 | 56.82 |
Nov-5 | 58.00 | 58.72 | 58.74 | 57.09 |
Nov-6 | 60.55 | 60.65 | 61.49 | 58.01 |
Nov-7 | 60.66 | 59.65 | 60.95 | 58.76 |
Nov-8 | 59.65 | 61.01 | 61.19 | 59.14 |
Nov-11 | 61.13 | 61.09 | 62.13 | 60.55 |
Nov-12 | 61.08 | 59.64 | 62.02 | 59.24 |
Nov-13 | 59.79 | 58.61 | 60.37 | 58.46 |
Nov-14 | 58.25 | 53.96 | 59.80 | 53.84 |
Nov-15 | 48.81 | 45.65 | 49.64 | 45.63 |
Nov-18 | 45.66 | 42.57 | 45.71 | 42.01 |
Nov-19 | 43.81 | 44.81 | 45.30 | 42.65 |
Nov-20 | 44.57 | 45.76 | 46.20 | 44.10 |
Halozyme Therapeutics Earnings
Halozyme Therapeutics Earnings Report: Per Share Halozyme Therapeutics Earnings Q1 Q2 Q3 and Q4 last year and next year.
Halozyme Therapeutics Forecast Revenue Growth
Halozyme Therapeutics Stock Analysis: Historical quarterly revenues per share for Halozyme Therapeutics and historical quarterly revenue growth:
- Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.35 per share, and an increase next year of $0.56 per share.
* Halozyme Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.